CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
Drug: OP0201 +1 morecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03748758
NCT03748758Phase 1Completed
CompareCT.gov

Evaluation of Safety of Repeated Doses of OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adult Volunteers

Novus Therapeutics, Inc·interventional·Posted Nov 21, 2018·Updated Feb 25, 2020

In Brief

A Phase 1 clinical trial evaluating Drug: OP0201 and Drug: Placebo for Healthy Adult Volunteers. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety and tolerability of two dose levels of OP0201 and placebo, when administered intranasally in healthy adults subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Adult Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedNov 21, 2018
Enrollment StartNov 27, 2018
Primary CompletionMar 20, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7.6 years ago

Interventions

Drug: OP0201combination

Drug OP0201

Drug: Placebocombination

Placebo